International Journal of Preventive Medicine (Int J Prev Med)2008-780210122020031522022202ENHypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, IsfahanCardiovascular Research Institute, Isfahan University of Medical Sciences, IsfahanInterventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, IsfahanDepartment of Neurology, Medical School, Isfahan University of Medical Sciences, Isfahan20200315<p><span class="fontstyle0"><strong>Context</strong>: </span><span class="fontstyle2">Mitoxantrone (MTX) is an antracyclin drug that is used for treatment of patients with<br />chronic refractory multiple sclerosis (MS). Congestive heart failure (CHF) is a rare complication of<br />this drug that may occur early, during therapy, or late, months or years after termination of therapy.<br /></span></p><p><span class="fontstyle0"><strong>Aims</strong>: </span><span class="fontstyle2">The aim of this study is to evaluate the long‑term adverse effect of MTX on cardiac function.<br /></span></p><p><span class="fontstyle0"><strong>Methods</strong>: </span><span class="fontstyle2">The study involved 49 MS patients on MTX therapy because of their disease was refractory<br />to other treatments (18 men and 31 women). They were treated in two canters related to Esfahan<br />University of Medical Sciences. The mean age was 34.65 ± 9.56 years. Systolic and diastolic left<br />ventricular (LV) functions were measured by echocardiography. The baseline echocardiographic data<br />were collected from patients’ file. Echocardiography was repeated by a single cardiologist in 2016.<br /></span></p><p><span class="fontstyle0"><strong>Results</strong>: </span><span class="fontstyle2">After MTX therapy, one patient’s ejection fraction (EF) reduced below 50% (2%). In spite<br />of their normal diastolic function before therapy, two patients developed diastolic dysfunction (4%).<br />Nonparametric binominal analysis reveals that MTX therapy increased the probability of developing<br />systolic dysfunction, early or late </span><span class="fontstyle3">P </span><span class="fontstyle2">&lt; 001.</span></p><p><strong></strong><span class="fontstyle0"><strong>Conclusions</strong>: </span><span class="fontstyle2">MS patients treated with MTX are at<br />increased risk of developing early and late‑LV dysfunction, so all patients on MTX therapy must be<br />periodically evaluated for these late complications.<br /></span></p><p><span class="fontstyle0" style="color: #00652e;"><strong>Keywords</strong>: </span><span class="fontstyle3">Heart failure, mitoxantrone, multiple sclerosis</span></p>http://ijpm.mui.ac.ir/index.php/ijpm/article/view/2202http://ijpm.mui.ac.ir/index.php/ijpm/article/download/2202/717718001